Boston Scientific stock absorbs a USD 20.00 target cut
Published on 09/30/2026 at 12:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific stock (ISIN US10117L1017) is confronting a USD 20.00 Oppenheimer price-target cut after an August cybersecurity incident disrupted manufacturing and shipments. The firm lowered its target from USD 85.00 to USD 65.00 on September 21, 2026, while retaining an Outperform rating, according to Yahoo Finance.
Cyber incident changes 2026 outlook
Boston Scientific identified unauthorized activity on August 25, 2026, and said the resulting network outage affected manufacturing, order processing and customer shipments. In its September 8, 2026 filing, the company said the incident was likely to have a material impact on third-quarter and full-year 2026 results.
The filing also said Boston Scientific expected to update its operational and financial outlook on October 28, 2026, when it discusses third-quarter results. Major distribution centers were processing orders at or above normal operating levels, while manufacturing had resumed across most facilities globally, according to the SEC filing.
Second-quarter growth remains measurable
The operational setback follows a second quarter that still delivered USD 5.442 billion in net sales, up 7.5 percent from the year-earlier period. Adjusted EPS was USD 0.86, compared with USD 0.75 a year earlier and above the company's USD 0.82 to USD 0.84 guidance range.
Boston Scientific's Cardiovascular business generated USD 3.624 billion in second-quarter sales, up 8.3 percent, while MedSurg sales reached USD 1.818 billion, up 5.9 percent. The reported results and 2026 outlook were published in the company's newsroom.
Targets remain split among analysts
MarketBeat reported on September 30, 2026, that thirty-one research firms carried an average 12-month price objective of USD 70.19. The tally included twenty-three buy ratings, six holds and two sells, while Wells Fargo had cut its target from USD 50.00 to USD 48.00 on September 23, 2026, according to MarketBeat.
Market value and trading venue
Boston Scientific had a market capitalization of USD 65.2 billion and a 52-week range of USD 42.20 to USD 105.65 as of September 29, 2026. The shares are listed on the New York Stock Exchange under ticker BSX, according to the company's September 7, 2026 filing.
Boston Scientific stock facts
- Company: Boston Scientific Corporation
- ISIN: US10117L1017
- Ticker: BSX
- Primary exchange: New York Stock Exchange
- Market capitalization: USD 65.2 billion as of September 29, 2026
- 52-week range: USD 42.20-105.65 as of September 29, 2026
- Sector / Industry: Healthcare / Medical Devices
